Semaglutide, tirzepatide join WHO list in hope of boosting access in low-income countries
(Newser) -
For the first time, the World Health Organization has named popular GLP-1 weight loss drugs as essential medicines, a move set to reshape access to the treatments in countries with limited healthcare resources. The move means semaglutide, the active ingredient in Novo Nordisk's Ozempic, and tirzepatide, the active...